What changed: Metastatic castration-resistant prostate cancer
Every dated change on the records linked to Metastatic castration-resistant prostate cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Approval10Regulatory4Trial result8Milestone10This record1
September 2026 · 1
2026 · 1
March 2025 · 1
2025 · 4
- 2025ApprovalLutetium-177 vipivotide tetraxetanLutetium-177 vipivotide tetraxetan approved in US
PSMA+ mCRPC after ARPI, before chemotherapy
- 2025Trial resultECLIPSEECLIPSE reported
rPFS significantly improved.
- 2025Trial resultENZA-pENZA-p reported
Adding adaptive-dosed 177Lu-PSMA-617 to enzalutamide improved PSA progression-free survival (13.
- 2025MilestoneECLIPSEECLIPSE: 177Lu-PSMA-I&T meets its endpoint
A milestone in how this cancer is treated.
2024 · 1
May 2023 · 1
2023 · 2
March 2022 · 1
2022 · 3
- 2022ApprovalLutetium-177 vipivotide tetraxetanLutetium-177 vipivotide tetraxetan approved in EU
mCRPC post-ARPI and taxane; pre-chemo 2025
- 2022ApprovalLutetium-177 vipivotide tetraxetanLutetium-177 vipivotide tetraxetan approved in US
PSMA+ mCRPC after ARPI and taxane
- 2022MilestoneMetastatic castration-resistant prostate cancerPROpel and MAGNITUDE: PARP inhibitor plus abiraterone
A milestone in how this cancer is treated.